SCHEMBL16632648

SCHEMBL16632648

Cc1cc2c(Br)cccn2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.38
KDM4E B2RXH2 7/20 0.38
CHRNA7 P36544 1/20 0.37
NPC1 O15118 7/20 0.35
RAB9A P51151 7/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 1/20 0.35
RECQL P46063 1/20 0.35
GRM5 P41594 5/20 0.35
GAA P10253 3/20 0.34
NFKB1 P19838 2/20 0.34
NFKB2 Q00653 2/20 0.34
RELA Q04206 2/20 0.34
HPGD P15428 3/20 0.32
ALOX12 P18054 1/20 0.32
APP P05067 1/20 0.32
PAX8 Q06710 1/20 0.32
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7167679 0.79 ALDH1A1 (0.56) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL16644707 0.76 GRM5 (0.38) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL23385228 0.76 ALDH1A1 (0.38) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL26422705 0.76 KDM4E (0.38) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL26422702 0.76 ALDH1A1 (0.45) ALDH1A1KDM4ECHRNA7NPC1RAB9A
SCHEMBL7170576 0.75 ALDH1A1 (0.43) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL7169392 0.72 TSHR (0.39) ALDH1A1KDM4ENPC1RAB9AGRM5
SCHEMBL16632641 0.72 GRM5 (0.38) ALDH1A1KDM4ECHRNA7GRM5GAA
SCHEMBL26422707 0.72 ALDH1A1 (0.38) ALDH1A1KDM4ENPC1RAB9AGRM5
SCHEMBL29837278 0.71 PSIP1 (0.39) ALDH1A1KDM4ECHRNA7NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR ALDH1A1 1200/4885KDM4E 2839/4885CHRNA7 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.